2887-LB: Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System

Introduction and Objective: The Omnipod Discover data management system was developed to enhance Omnipod 5 user and HCP engagement with diabetes data, displaying an ambulatory glucose profile alongside time-of-day device settings and bolus frequency. This real-world analysis evaluated the association between Discover initiation and glycemic outcomes of current Omnipod 5 users. Methods: A retrospective analysis of CGM and insulin data from US Omnipod 5 users with T1D (≥2y) and T2D (≥18y) with ≥6months of Omnipod 5 use pre- and post-Omnipod Discover enrollment was conducted. Users with sufficient CGM data (≥14 days of CGM readings, ≥75% of days with ≥220 readings) in the last 30 days of pre- and post-enrollment periods and who engaged with Omnipod Discover ≥1 time post-enrollment were included. Glycemic outcomes were compared pre- and post-enrollment. Results: A total of 245 users (median age 31y; 34% aged 2-17y, 66% aged ≥18y) met inclusion criteria. Median TIR 70-180mg/dL increased by 1.8% [95% CI -1.4, 3.5] from 68.9% to 70.7%, with 32% of users experiencing a clinically meaningful increase of 3%. Those with baseline TIR <60% saw the greatest increase in TIR ranging from 1.4%-5.1% across groups (Fig A), while TBR <70mg/dL remained low across subjects (Fig B). Conclusion: The glycemic improvement observed following initiation of Omnipod Discover in current Omnipod 5 users supports the impact that enhanced data presentation may have in diabetes management. Disclosure P.F. Mora: Speaker's Bureau; Current; Abbott Diabetes. Advisory Panel; Current; Novo Nordisk. Speaker's Bureau; Current; Novo Nordisk, Dexcom, Inc. Consultant; Current; Medtronic. Speaker's Bureau; Current; Insulet Corporation. C. Berget: Consultant; Current; Insulet Corporation. Consultant; Ended; Medtronic. Advisory Panel; Current; Tandem Diabetes Care, Inc. Consultant; Current; Tandem Diabetes Care, Inc. Advisory Panel; Current; Sequel. M.M. Sarkar: Speaker's Bureau; Ended; Boehringer Ingelheim International GmbH. Speaker's Bureau; Current; CeQur SA, Dexcom, Inc., Insulet Corporation, MannKind Corporation, Sanofi, Xeris Pharmaceuticals, Inc. M. Novak: Employee; Current; Insulet Corporation. Employee; Ended; Abbott Diabetes. D. Do: Employee; Current; Insulet Corporation. T.T. Ly: Employee; Current; Insulet Corporation. Stock/Shareholder; Current; Insulet Corporation.